News
Current Press Release
ClearLight Biotechnologies, LLC (ClearLight) is recognized as one of the “15 Most Promising BioTech Startups of 2018”.
Posted on Nov 13, 2018
SUNNYVALE, Calif., November 13, 2018 (PR NEWSWIRE)
ClearLight Biotechnologies, LLC (ClearLight) a developer of an automated next generation tissue processing platform and proprietary 3D image analysis software for research and future diagnostic applications, is recognized as one of the “15 Most Promising BioTech Startups for 2018”. Recipients of this honor is decided by a distinguished panel of biotechnology experts, including CEOs, CIOs, VCs analysts and the editorial board of StartupCity magazine.
“It is an honor to be recognized for our efforts and as such, it is our mission to revolutionize the diagnostic, prognostic, and predictive treatment of disease by enabling next generation technologies for non-destructively processing and digitally analyzing tissue in 3D.” said Laurie Goodman, Ph.D., CEO. “This recognition will serve to inform the marketplace of our current short and longer-term business plans as well as our potential future commercialization plan to introduce a Research Use Only (RUO) platform.” stated Dr. Goodman.
Please visit and follow us at:
Website: www.clearlightbiotechnologies.com
LinkedIn: https://www.linkedin.com/in/clearlight-biotechnologies-llc-ab0970172/
Twitter: https://twitter.com/ClearlightBio
YouTube: https://www.youtube.com/channel/UCXKptXdwz68uZEo8Z-CiRsw
About ClearLight
Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing an automated instrumentation platform based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and analysis of heterogeneous cellular interactions within the microenvironment of a tissue. This technology, paired with a multi-sample tissue imaging and proprietary 3D image analysis software, will enable more accurate analysis and assessment of normal and diseased tissue.
Visit us: www.clearlightbiotechnologies.com
Contact: Laurie Goodman, Ph.D., CEO
contact@clearlightbiotech.com
(800) 251-8905